Eckert & Ziegler’s Theralugand® Gains EU Approval for Advanced Cancer Therapies

Eckert & Ziegler’s Theralugand® Gains EU Approval for Advanced Cancer Therapies

(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate cancer, moving beyond investigational use in clinical trials. Eckert & Ziegler is increasing production capacity to meet growing demand and support global access to innovative radiopharmaceutical treatments. CEO Dr. Harald Hasselmann emphasized the company’s commitment to advancing cancer care and providing reliable therapeutic solutions.

(PRESS RELEASE) BERLIN, 27-Nov-2024 — /EuropaWire/ — Eckert & Ziegler Radiopharma GmbH has announced that the European Commission has approved its proprietary Lutetium-177 chloride, Theralugand®, for routine clinical use throughout the European Economic Area (EEA). This milestone paves the way for the radiopharmaceutical to support innovative cancer treatments targeting conditions such as neuroendocrine tumors and metastatic prostate cancer.

Theralugand® offers high-purity, non-carrier-added Lutetium-177 produced under GMP standards, specifically designed for labeling therapeutic radiopharmaceuticals. Until now, Lutetium-177 from Eckert & Ziegler had been restricted to investigational use in clinical trials. The approval enables its broader application in routine treatments, marking a significant advancement in the availability of targeted radiotherapies across Europe.

Driving Innovation in Cancer Care

Eckert & Ziegler collaborates with pharmaceutical partners worldwide to advance Lutetium-177-based radiopharmaceuticals, playing a vital role in expanding access to targeted cancer therapies. “The approval of Theralugand® is a major milestone in our mission to provide innovative and reliable therapeutic radiopharmaceuticals,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This achievement reflects our commitment to enhancing treatment options for patients across Europe.”

Meeting Rising Demand

To address the growing global need for Lutetium-177, Eckert & Ziegler is increasing its production capacity to ensure a stable and reliable supply of this critical radioisotope, supporting the expansion of targeted therapies worldwide.

With this approval, Theralugand® is poised to play a key role in advancing cancer treatments and improving patient outcomes throughout Europe.

About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Media Contacts:

Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

SOURCE: Eckert & Ziegler SE